ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,502.35
-0.73%
Dow Jones
44,421.85
-0.32%
Gold vs US Dollar
2,774.265
0.66%
Brent Oil
77.705
0.48%
Bitcoin
105,787.10
1.75%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Sutro Biopharma Inc (STRO)

  7. Sutro Biopharma Inc (STRO) News

Sutro Biopharma (STRO)

Sutro Biopharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:STRO
DateTimeSourceHeadlineSymbolCompany
07/01/202521:05GlobeNewswire Inc.Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference NASDAQ:STROSutro Biopharma Inc
07/01/202514:00GlobeNewswire Inc.Sutro Biopharma and Boehringer Ingelheim BioXcellenceâ„¢ collaboration: Established first-in-class cell-free capabilities at commercial scaleNASDAQ:STROSutro Biopharma Inc
10/12/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
10/12/202413:00GlobeNewswire Inc.Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian CancerNASDAQ:STROSutro Biopharma Inc
03/12/202421:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
15/11/202400:54Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:STROSutro Biopharma Inc
13/11/202421:34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STROSutro Biopharma Inc
13/11/202421:30Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:STROSutro Biopharma Inc
13/11/202421:30GlobeNewswire Inc.Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business HighlightsNASDAQ:STROSutro Biopharma Inc
12/11/202414:34Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:STROSutro Biopharma Inc
04/11/202421:05GlobeNewswire Inc.Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC ConferenceNASDAQ:STROSutro Biopharma Inc
01/11/202412:00GlobeNewswire Inc.Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AMLNASDAQ:STROSutro Biopharma Inc
10/10/202420:05GlobeNewswire Inc.Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research ForumNASDAQ:STROSutro Biopharma Inc
20/09/202420:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
20/09/202420:01GlobeNewswire Inc.Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:STROSutro Biopharma Inc
14/09/202407:00GlobeNewswire Inc.Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024NASDAQ:STROSutro Biopharma Inc
11/09/202412:00GlobeNewswire Inc.Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024NASDAQ:STROSutro Biopharma Inc
22/08/202412:00GlobeNewswire Inc.Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung CancerNASDAQ:STROSutro Biopharma Inc
13/08/202420:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STROSutro Biopharma Inc
13/08/202420:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
13/08/202420:30GlobeNewswire Inc.Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesNASDAQ:STROSutro Biopharma Inc
13/08/202420:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
12/08/202420:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
12/08/202420:38Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
12/08/202420:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
10/07/202420:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
10/07/202420:10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
09/07/202412:00GlobeNewswire Inc.Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development OfficerNASDAQ:STROSutro Biopharma Inc
10/06/202420:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
10/06/202420:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:STRO

Your Recent History

LSE
VAST
Vast Resources
LSE
TERN
Tern
LSE
AAZ
Anglo Asian Mining
LSE
SBTX
Skinbiotherapeutics
LSE
QBT
Quantum Blockchain Techn...
LSE
SYME
Supply@me Capital
LSE
PANR
Pantheon Resources
LSE
MIN
Minoan
LSE
POS
Plexus
LSE
EME
Empyrean Energy
LSE
NFDS
Northern Foods
LSE
BOO
Boohoo
LSE
ITM
Itm Power
LSE
AGL
Angle
LSE
GWMO
Great Western Mining
LSE
ASLI
Abrdn European Logistics...
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads